依洛尤单抗联合阿托伐他汀治疗症状性颅内动脉粥样硬化狭窄的疗效

doi:10.3969/j.issn.1671-7171.2026.02.029

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1148 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】 观察依洛尤单抗联合阿托伐他汀治疗症状性颅内动脉粥样硬化狭窄(ICAS)患者的疗效。【方法】 116例症状性ICAS患者随机分为对照组与观察组,每组58例。对照组给予阿托伐他汀钙片治疗,观察组在对照组的基础上联合应用依洛尤单抗治疗。比较两组患者治疗前后的血脂水平、颈动脉内膜中层厚度(CIMT)、斑块厚度、血清淀粉样蛋白A1(SAA1)水平、脑血容量(CBV)和脑血流量(CBF),用药期间不良反应发生情况。记录患者治疗1年后的脑梗死再发、脑动脉再狭窄、死亡等不良终点事件发生率。【结果】 观察组经过治疗后血脂水平较对照组明显改善,CIMT、斑块面积和血清SAA1水平低于对照组,CBV、CBF高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。观察组患者不良终点事件发生率低于对照组(P<0.05)。【结论】 依洛尤单抗联合阿托伐他汀可更有效改善症状性ICAS患者的血脂水平、颈动脉病变及脑血流,且安全性良好,能降低不良终点事件发生率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	毛镇亚
	陈建溯

关键词 ：颅内动脉硬化, 抗体,单克隆, 阿托伐他汀, 治疗结果

Abstract：【Objective】 To investigate the efficacy of evolocumab combined with atorvastatin in the treatment of patients with symptomatic intracranial atherosclerotic stenosis (ICAS). 【Methods】 A total of 116 patients with symptomatic ICAS were randomly divided into the control group and the observation group, with 58 cases in each group. The control group was treated with atorvastatin calcium tablets, while the observation group was administered with evolocumab in addition to the control group's regimen. The blood lipid levels, carotid intima-media thickness (CIMT), plaque thickness, serum amyloid A1 (SAA1), cerebral blood volume (CBV) and cerebral blood flow (CBF) before and after treatment, as well as the incidence of adverse reactions during medication were compared between the two groups. The incidence of adverse endpoint events such as recurrent cerebral infarction, restenosis and death within 1 year after treatment was recorded. 【Results】 After treatment, the blood lipid metabolism level in the observation group was significantly improved compared with that in the control group. The levels of CIMT, plaque thickness and serum SAA1 in the observation group were lower than those in the control group, while CBV and CBF were higher than those in the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). The incidence of adverse endpoint events in the observation group was lower than that in the control group (P<0.05). 【Conclusion】 Evolocumab combined with atorvastatin can more effectively improve the blood lipid profile, carotid artery lesions and cerebral blood flow status of patients with symptomatic ICAS safely. It reduces the incidence of adverse endpoint events.

Key words： Intracranial Arteriosclerosis Antibodies, Monoclonal Atorvastatin Treatment Outcome

收稿日期: 2025-10-23

中图分类号:

R743.1

引用本文:

毛镇亚, 陈建溯. 依洛尤单抗联合阿托伐他汀治疗症状性颅内动脉粥样硬化狭窄的疗效[J]. 医学临床研究, 2026, 43(2): 284-286.
MAO Zhenya, CHEN Jiansu. Efficacy of Evolocumab Combined with Atorvastatin in the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis. JOURNAL OF CLINICAL RESEARCH, 2026, 43(2): 284-286.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2026.02.029 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2026/V43/I2/284

[1] 蒋兰,孙梦飞,李怡萍,等. PCSK9抑制剂在症状性颅内动脉粥样硬化狭窄患者早期强化降脂治疗的作用[J].临床神经病学杂志,2024,37(5):350-355.
[2] 李卫征,武国良,吴强. 依达拉奉右莰醇与阿托伐他汀对老年急性脑梗死伴颅内动脉狭窄患者脂代谢及炎症影响[J].中华老年心脑血管病杂志,2023,25(1):57-61.
[3] 张静,芦亚兰,何勐,等. 依洛尤单抗联合瑞舒伐他汀治疗急性冠状动脉综合征的临床研究[J].中国合理用药探索,2024,21(8):79-85.
[4] SAMULS O B, JOSEPH G J, LYNN M J,et al. A standardized method for measuring intracranial arterial stenosis[J].AJNR Am J Neuroradiol,2000, 21(4):643-646.
[5] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中. 中国急性缺血性脑卒中诊治指南2010[J].中国全科医学,2011,14(35):4013-4017.
[6] 王伊龙,陈玮琪,刘欣如,等. 中国脑血管病临床管理指南(第2版)(节选):第3章脑血管病高危人群管理[J].中国卒中杂志,2023,18(8):898-909.
[7] 高鹏,王志飞. 中国颅内动脉粥样硬化性狭窄介入治疗的现状与未来[J].中国脑血管病杂志,2023,20(5):289-297.
[8] JADHAV S B, CRASS R L, CHAPEL S,et al. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model[J].Eur Heart J Card Pharmacother,2022, 8(6):578-586.
[9] LEHRKE M, VOGT A, SCHETTLER V, et al. Evolocumab-based LDL-C management in high and very high cardiovascular risk patients in german clinical practice: the HEYMANS study[J].Adv Ther,2024, 41(3):1184-1200.
[10] 刘惠,蒋萌,束宁德,等. 针对动脉粥样硬化性心脑血管疾病的新型降脂药物的作用机制及研究进展[J].中国医学创新,2024,21(5):157-164.
[11] DI FUSCO S A, ARCA M, SCICCHITANO P,et al. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target[J].Heart,2022,109(1):18-25.
[12] GERMAN C A, LIAO J K. Understanding the molecular mechanisms of statin pleiotropic effects[J].Arch Toxicol,2023, 97(6):1529-1545.
[13] 吴小燕,肖凯,文晓柯,等. 新型降脂药物PCSK9抑制剂临床疗效研究进展[J].中国医药导刊,2024,26(3):231-235.
[14] JIA X, LIU Z T, WANG Y X,et al. Serum amyloid A and interleukin -1β facilitate LDL transcytosis across endothelial cells and atherosclerosis via NF-κB/caveolin-1/cavin-1 pathway[J].Atherosclerosis,2023, 375(1):87-97.
[15] 路怀志,赵辉,王勇,等. 前蛋白转化酶枯草溶菌素9抑制剂作为一级预防治疗对兔动脉粥样硬化斑块发生与进展的影响[J].中国医药,2024,19(8):1137-1141.